Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bridgebio Pharma Inc
(NQ:
BBIO
)
24.96
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Bridgebio Pharma Inc
< Previous
1
2
3
4
5
6
Next >
Why BridgeBio Pharma Stock Is Hitting New 52-Week Highs Monday
March 06, 2023
BridgeBio Pharma Inc (NASDAQ: BBIO) shares are ripping higher Monday morning after the company announced positive data for its phase 2 study of
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
March 06, 2023
Via
Benzinga
Looking Into BridgeBio Pharma's Return On Capital Employed
February 28, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
February 16, 2023
Via
Benzinga
Why BridgeBio Pharma Stock Is Shooting Higher
December 29, 2022
BridgeBio Pharma Inc (NASDAQ: BBIO) shares are trading higher by 16.77% to $7.87 Thursday afternoon after the company initiated its CALIBRATE Phase 3 study of Encaleret. What Else?
Via
Benzinga
Looking Into BridgeBio Pharma's Return On Capital Employed
November 23, 2022
Via
Benzinga
BridgeBio Pharma: Q3 Earnings Insights
November 03, 2022
BridgeBio Pharma (NASDAQ:BBIO) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Via
Benzinga
BridgeBio Pharma Shares Preliminary Data From Gene Therapy Candidate In Ultra Rare Disorder
October 14, 2022
Via
Benzinga
LianBio To Shut BridgeBio-Partnered Bile Duct Cancer Drug Trial
October 13, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 6, 2023
February 06, 2023
Via
Benzinga
BridgeBio Pharma Earnings Perspective: Return On Capital Employed
August 25, 2022
According to Benzinga Pro data, during Q2, BridgeBio Pharma (NASDAQ:BBIO) posted sales of $73.75 million. Earnings were up 98.73%, but BridgeBio Pharma still reported an overall loss of $2.56 million.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
August 25, 2022
Via
Benzinga
BridgeBio Starts Dosing In Early-Stage Genetic Metabolism Disorder Trial
August 18, 2022
Via
Benzinga
BridgeBio Pharma Touts Encouraging Data From Dwarfism Candidate
July 26, 2022
Via
Benzinga
BridgeBio Pharma Posts Promising Data From Gene Therapy Trial In Ultra-Rare Disease
June 22, 2022
Via
Benzinga
Why Hoth Therapeutics Shares Are Trading Higher By More Than 130%? Here Are 60 Stocks Moving In Thursday's Mid-Day Session
December 29, 2022
Gainers Hoth Therapeutics, Inc. (NASDAQ: HOTH) shares jumped 131.5% to $10.19 after the FDA accepted the IND application for HT-001.
Via
Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
August 18, 2022
Via
Benzinga
BridgeBio Pharma Posts Early Data From Neurological Movement Disorder Candidate
May 26, 2022
Via
Benzinga
Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
September 14, 2022
Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX...
Via
Benzinga
BridgeBio Shares Fall As Initial-Stage Rare Metabolic Disorder Study Kicks-off
August 18, 2022
BridgeBio Pharma (NASDAQ: BBIO) has dosed first patient in its Phase 1 clinical trial of BBP-671, an investigational oral therapy being developed for the potential treatment of conditions caused by...
Via
Benzinga
Why Amazon, Microsoft, Apple Shares Are Trading Lower, Here Are 50 Stocks Moving In Tuesday's Mid-Day Session
September 13, 2022
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 186% to $47.69 as the stock started trading on a 1-for-30 reverse split basis.
Via
Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
August 10, 2022
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
August 03, 2022
Via
Benzinga
Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday
July 27, 2022
Gainers Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) shares surged 94.3% to close at $1.69 on Tuesday after the company filed a request for the withdrawal of the Registration Statement on Form S-1.
Via
Benzinga
Recap Of Tuesday's Biotech Catalysts - End of The Day Summary
July 26, 2022
Via
Benzinga
BridgeBio Pharma Reveals Early Positive Data For Canavan Disease
June 22, 2022
BridgeBio Pharma (NASDAQ: BBIO) announced early positive data from the the first two participants dosed in CANaspire clinical study for the treatment of Canavan disease.
Via
Benzinga
89 Biggest Movers From Friday
June 21, 2022
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.
Via
Benzinga
BridgeBio Pharma's Return On Capital Employed Insights
May 31, 2022
Benzinga Pro data, BridgeBio Pharma (NASDAQ:BBIO) reported Q1 sales of $1.69 million. Earnings fell to a loss of $201.33 million, resulting in a 32.21% decrease from last quarter.
Via
Benzinga
6 Analysts Have This to Say About BridgeBio Pharma
May 24, 2022
Over the past 3 months, 6 analysts have published their opinion on BridgeBio Pharma (NASDAQ:BBIO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...
Via
Benzinga
BridgeBio Partnered Protein Replacement Therapy Shows Promising Action In Painful Skin Blistering Disorder
May 20, 2022
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.